Fi­bro­Gen, fresh off da­ta ma­nip­u­la­tion scan­dal, touts win in can­cer pa­tients with­out re­veal­ing da­ta

Fi­bro­Gen’s lead drug has cleared an­oth­er mid-stage study. Or at least the biotech claims it has.

Fi­bro­Gen, a 28-year-old com­pa­ny whose stock col­lapsed this past …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER